ABSTRACT
Description: Zenapax is a humanized monoclonal antibody with specific binding activity for the α-chain (also known as CD25 or Tac) of the interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes. It is produced using recombinant DNA technology in NSO myeloma cells and supplied as a concentrated solution (5 mg/ml) for intravenous infusion.
